Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

CASE:RMDA Stock Report

Market Cap: ج.م5.1b

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Valuation

Is RMDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RMDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RMDA (EGP3.41) is trading below our estimate of fair value (EGP5.28)

Significantly Below Fair Value: RMDA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RMDA?

Key metric: As RMDA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RMDA. This is calculated by dividing RMDA's market cap by their current earnings.
What is RMDA's PE Ratio?
PE Ratio19.3x
Earningsج.م266.06m
Market Capج.م5.13b

Price to Earnings Ratio vs Peers

How does RMDA's PE Ratio compare to its peers?

The above table shows the PE ratio for RMDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.2x
PHAR Egyptian International Pharmaceutical Industries
5.6xn/aج.م6.6b
BIOC GlaxoSmithKlineE
26.3xn/aج.م3.1b
AXPH Alexandria For Pharmaceuticals & Chemical Industries
7.4xn/aج.م1.6b
OCPH October PharmaE
9.7xn/aج.م1.3b
RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E
19.3x30.7%ج.م5.1b

Price-To-Earnings vs Peers: RMDA is expensive based on its Price-To-Earnings Ratio (19.3x) compared to the peer average (12.2x).

Price to Earnings Ratio vs Industry

How does RMDA's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
RMDA 19.3xIndustry Avg. 12.8xNo. of Companies4PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RMDA is expensive based on its Price-To-Earnings Ratio (19.3x) compared to the African Pharmaceuticals industry average (12.6x).

Price to Earnings Ratio vs Fair Ratio

What is RMDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RMDA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RMDA's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RMDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentج.م3.41
ج.م5.02
+47.3%
36.4%ج.م9.00ج.م3.58n/a6
Dec ’25ج.م3.58
ج.م5.02
+40.3%
36.4%ج.م9.00ج.م3.58n/a6
Nov ’25ج.م3.59
ج.م4.11
+14.5%
11.9%ج.م5.00ج.م3.58n/a5
Oct ’25ج.م3.10
ج.م4.11
+32.6%
11.9%ج.م5.00ج.م3.58n/a5
Sep ’25ج.م2.37
ج.م4.41
+86.1%
18.3%ج.م5.70ج.م3.58n/a5
Aug ’25ج.م2.33
ج.م4.41
+89.3%
18.3%ج.م5.70ج.م3.58n/a5
Jul ’25ج.م2.37
ج.م4.41
+86.1%
18.3%ج.م5.70ج.م3.58n/a5
Jun ’25ج.م2.35
ج.م4.38
+86.3%
19.3%ج.م5.70ج.م3.42n/a5
May ’25ج.م2.06
ج.م4.00
+94.1%
28.7%ج.م5.70ج.م2.10n/a6
Apr ’25ج.م2.70
ج.م3.81
+41.2%
34.2%ج.م5.70ج.م2.10n/a6
Mar ’25ج.م2.90
ج.م3.62
+24.7%
37.4%ج.م5.70ج.م2.10n/a6
Feb ’25ج.م2.01
ج.م2.41
+19.7%
17.9%ج.م3.00ج.م1.84n/a5
Jan ’25ج.م1.65
ج.م2.38
+44.0%
18.6%ج.م3.00ج.م1.84n/a5
Dec ’24ج.م1.67
ج.م2.33
+39.2%
20.5%ج.م3.00ج.م1.84ج.م3.585
Nov ’24ج.م1.52
ج.م2.26
+48.5%
18.4%ج.م2.96ج.م1.84ج.م3.595
Oct ’24ج.م1.41
ج.م2.33
+64.5%
17.7%ج.م2.96ج.م1.84ج.م3.105
Sep ’24ج.م1.39
ج.م2.34
+67.9%
17.0%ج.م2.96ج.م1.90ج.م2.375
Aug ’24ج.م1.43
ج.م2.34
+64.1%
17.0%ج.م2.96ج.م1.90ج.م2.335
Jul ’24ج.م1.56
ج.م2.35
+50.3%
16.5%ج.م2.96ج.م1.90ج.م2.375
Jun ’24ج.م1.53
ج.م2.35
+53.5%
16.5%ج.م2.96ج.م1.90ج.م2.355
May ’24ج.م1.46
ج.م2.26
+54.4%
10.8%ج.م2.50ج.م1.96ج.م2.065
Apr ’24ج.م1.30
ج.م2.26
+73.9%
10.8%ج.م2.50ج.م1.96ج.م2.705
Mar ’24ج.م1.55
ج.م2.15
+39.0%
11.8%ج.م2.46ج.م1.81ج.م2.905
Feb ’24ج.م1.75
ج.م2.18
+24.3%
13.1%ج.م2.56ج.م1.81ج.م2.015
Jan ’24ج.م1.95
ج.م2.18
+11.8%
13.1%ج.م2.56ج.م1.81ج.م1.655
Dec ’23ج.م1.93
ج.م2.18
+12.9%
13.1%ج.م2.56ج.م1.81ج.م1.675

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 08:07
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eman MareeArab African International Securities
Ahmed RashadBeltone Financial
Aly AdelBeltone Financial